San Francisco-based RDMD, a biopharma startup dedicated to accelerating research for patients with rare diseases, announced its $3 million seed financing backed by Lux Capital and Village Global, whose network of backers include Bill Gates, Mark Zuckerberg, Jeff Bezos, and Reid Hoffman. RDMD has developed a technology platform that generates deep data insights to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to get
Read More
Biomarker-Guided Drug Development
Genetic Material Once Considered Junk Actually Could Hold Key to Cancer Drug Response
Material left out of common processes for sequencing genetic material in cancer tumors may actually carry important information about why only some people respond to immunotherapy, possibly offering better insight than the type of material that is being sequenced, according to a study by Mount Sinai researchers published on April 3 in Cell Reports. Sequencing a type of genetic material in cancer tumors called messenger RNA has transformed personalized cancer therapy and revealed biomarkers for
Read More
Precision Medicine Group Raises $275M to Support Biomarker-Guided Drug Development
Precision Medicine Group (PMG), an integrated team of experts focused on biomarker-guided drug development has raised $275 million in funding led by Berkshire Partners and TPG Growth and also includes significant participation from Precision’s co-founders and management team as well as original investors Oak Investment Partners and J.H. Whitney. . This investment will support the expansion of PMG’s global footprint and provide additional scale to accelerate the development, approval and
Read More
